Rodrigo Ruiz‐Soto

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean‐Yves Blay, César Serrano, Michael C. Heinrich et al. · The Lancet Oncology · 2020 · 407 citations · Full text

Medicine, Oncology, Pharmacology +6

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Kathleen N. Moore, Lainie P. Martin, David M. O’Malley et al. · Journal of Clinical Oncology · 2017 · 219 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O’Malley et al. · Cancer · 2017 · 141 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Dysregulation of interleukin‐10 production in relatives of patients with systemic lupus erythematosus

Luis Llorente, Yvonne Richaud‐Patín, Jacques Couderc et al. · Arthritis & Rheumatism · 1997 · 132 citations

Life Sciences, Genetics, Immunology +11